MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 translational study.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516841-38-00

Enrollment

100

Registered

2025-01-09

Start date

2025-01-09

Completion date

Unknown

Last updated

2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

Brief summary

Primary endpoint -Progression Free Survival

Detailed description

Secondary endpoints -Overall Survival -Progression Free Survival 2 (after the subsequent line of treatment) -Toxicity (graded according to CTCAEv 5.0) -Response Rate (RECIST 1.1)

Interventions

DRUGLynparza 100 mg film-coated tablets

DRUGLynparza 150 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary endpoint -Progression Free Survival	—

Secondary

Measure	Time frame
Secondary endpoints -Overall Survival -Progression Free Survival 2 (after the subsequent line of treatment) -Toxicity (graded according to CTCAEv 5.0) -Response Rate (RECIST 1.1)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026